BIBLIOGRAPHIE

1: Carruthers J, Carruthers A.
Complications of botulinum toxin type a.
Facial Plast Surg Clin North Am. 2007 Feb;15(1):51-4. No abstract available.

2: Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY; the North
American Botox in Primary Axillary Hyperhidrosis Clinical Study Group.
Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: A
52-week multicenter double-blind, randomized, placebo-controlled study of
efficacy and safety.
J Am Acad Dermatol. 2007 Feb 14; [Epub ahead of print]

3: Healy B.
The botox balance.
US News World Rep. 2007 Jan 22;142(3):71. No abstract available.

4: Andrews M, Kotz D.
Smoothing the fault lines. When it comes to botox treatment, the devil is in
the details.
US News World Rep. 2007 Jan 22;142(3):69-70. No abstract available.

5: Venus MR.
Use of botulinum toxin type A to prevent widening of facial scars.
Plast Reconstr Surg. 2007 Jan;119(1):423-4; author reply 424. No abstract
available.

6: Carruthers A, Carruthers J, Cohen J.
Dilution volume of botulinum toxin type A for the treatment of glabellar
rhytides: does it matter?
Dermatol Surg. 2007 Jan;33(1 Spec No.):S97-104.

7: Smith KC, Comite SL, Storwick GS.
Ice minimizes discomfort associated with injection of botulinum toxin type A
for the treatment of palmar and plantar hyperhidrosis.
Dermatol Surg. 2007 Jan;33(1 Spec No.):S88-91.

8: Monheit G, Carruthers A, Brandt F, Rand R.
A randomized, double-blind, placebo-controlled study of botulinum toxin type A
for the treatment of glabellar lines: determination of optimal dose.
Dermatol Surg. 2007 Jan;33(1 Spec No.):S51-9.

9: Rzany B, Dill-Muller D, Grablowitz D, Heckmann M, Caird D; German-Austrian
Retrospective Study Group.
Repeated botulinum toxin A injections for the treatment of lines in the upper
face: a retrospective study of 4,103 treatments in 945 patients.
Dermatol Surg. 2007 Jan;33(1 Spec No.):S18-25.

10: Carruthers J, Carruthers A.
Botulinum toxin type A treatment of multiple upper facial sites:
patient-reported outcomes.
Dermatol Surg. 2007 Jan;33(1 Spec No.):S10-7.

11: Carruthers J, Carruthers A.
Complications of botulinum toxin type a.
Facial Plast Surg Clin North Am. 2007 Feb;15(1):51-4. No abstract available.

12: Carruthers A, Carruthers J, Cohen J.
Dilution volume of botulinum toxin type A for the treatment of glabellar
rhytides: does it matter?
Dermatol Surg. 2007 Jan;33(1 Spec No.):S97-104.

13: Carruthers A, Carruthers J, Flynn TC, Leong MS.
Dose-finding, safety, and tolerability study of botulinum toxin type B for the
treatment of hyperfunctional glabellar lines.
Dermatol Surg. 2007 Jan;33(1 Spec No.):S60-8.

14: Monheit G, Carruthers A, Brandt F, Rand R.
A randomized, double-blind, placebo-controlled study of botulinum toxin type A
for the treatment of glabellar lines: determination of optimal dose.
Dermatol Surg. 2007 Jan;33(1 Spec No.):S51-9.

15: Carruthers A, Carruthers J.
Eyebrow height after botulinum toxin type A to the glabella.
Dermatol Surg. 2007 Jan;33(1 Spec No.):S26-31.

16: Carruthers J, Carruthers A.
Botulinum toxin type A treatment of multiple upper facial sites:
patient-reported outcomes.
Dermatol Surg. 2007 Jan;33(1 Spec No.):S10-7.

17: Carruthers J, Carruthers A.
The use of botulinum toxin type A in the upper face.
Facial Plast Surg Clin North Am. 2006 Aug;14(3):253-60. No abstract available.

18: Coleman KR, Carruthers J.
Combination therapy with BOTOX and fillers: the new rejuvnation paradigm.
Dermatol Ther. 2006 May-Jun;19(3):177-88. Review.

19: Carruthers A, Carruthers J.
Botulinum treatment of forehead wrinkles.
Plast Reconstr Surg. 2006 Apr;117(4):1354; author reply 1355. No abstract
available.

20: Matarasso SL, Carruthers JD, Jewell ML; Restylane Consensus Group.
Consensus recommendations for soft-tissue augmentation with nonanimal
stabilized hyaluronic acid (Restylane).
Plast Reconstr Surg. 2006 Mar;117(3 Suppl):3S-34S; discussion 35S-43S.

21: Carruthers A, Carruthers J.
Single-center, double-blind, randomized study to evaluate the efficacy of 4%
lidocaine cream versus vehicle cream during botulinum toxin type A treatments.
Dermatol Surg. 2005 Dec;31(12):1655-9.

22: Carruthers A, Carruthers J.
Botulinum toxin type A.
J Am Acad Dermatol. 2005 Aug;53(2):284-90. No abstract available.

23: Carruthers J, Carruthers A.
Botulinum toxin below the eyes.
Int Ophthalmol Clin. 2005 Summer;45(3):133-41. No abstract available.

24: Dover JS, Carruthers A, Carruthers J, Alam M.
Clinical Use of RESTYLANE.
Skin Therapy Lett. 2005 Feb;10(1):5-7. Review. Erratum in: Skin Therapy Lett.
2005 Mar;10(2):9.

25: Carruthers J, Carruthers A.
Botulinum toxin A in the mid and lower face and neck.
Dermatol Clin. 2004 Apr;22(2):151-8.

26: Carruthers A, Carruthers J.
Botulinum toxin type A for the treatment of glabellar rhytides.
Dermatol Clin. 2004 Apr;22(2):137-44.

27: Scott AB.
Development of botulinum toxin therapy.
Dermatol Clin. 2004 Apr;22(2):131-3, v.

28: Carruthers J, Carruthers A.
Botox: beyond wrinkles.
Clin Dermatol. 2004 Jan-Feb;22(1):89-93. Review.

29: Hexsel D, Dal'forno T.
Type A botulinum toxin in the upper aspect of the face.
Clin Dermatol. 2003 Nov-Dec;21(6):488-97. Review.

30: Carruthers A.
History of the clinical use of botulinum toxin A and B.
Clin Dermatol. 2003 Nov-Dec;21(6):469-72.

Pour une bibliographie compléte : utilisez le site Pubmed.